159 COVID-positive patients will participate in Phase 2 of lagundi clinical trials, according to DOST
The Department of Science and Technology (DOST) had reported that 159 COVID-positive patients will participate in Phase 2 of lagundi (Chinese chaste tree) clinical trials.
In a report on Manila Bulletin, DOST Secretary Fortunato “Boy” T. de la Peña on Friday disclosed during his weekly report that more than 150 COVID-positive patients had been enrolled to participate in the Stage 2 of clinical trials on the use of lagundi as a therapeutic or supplement for COVID-19.
“On the project to evaluate the efficacy and safety of Lagundi tablets in patients without co-morbidities, suspected or with mild COVID-19: screening and recruitment of participants for stage 2 is ongoing,” de la Peña said.
De la Peña also noted that the project had enrolled a total of 159 participants from quarantine facilities or study sites as of March 26, 2021.
READ ALSO: VCO Decreases COVID-19 Symptoms Of Suspect, Probable Cases In Study, Says DOST
Manila Bulletin also reported that the breakdown of patients per site was as follows: 98 participants from Philippine National Police (PNP) Camp Bagong Diwa, 24 participants from Valenzuela Quarantine Facility, 23 participants from Quirino Institute, eight participants from Araullo High School, four participants from Rizal High School, and two participants from Silungan Molave, Diliman.
Dr. Cecilia Nelia C. Maramba-Lazarte of the University of the Philippines (UP) Manila announced in late March that the lagundi clinical trials were expected to be completed soon.
According to her, they completed the Stage 1 of the clinical trials or the dose-finding and safety study at the PNP Camp Bagong Final Special Care Facility and at the Quezon Institute.
For more news and updates, you may feel free to visit this site more often. You may also visit Newspapers.ph via our official Facebook page and YouTube channel.